7,9-二氢-3H-嘌呤-2,6,8-三硫酮 | 15986-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 7,9-二氢-3H-嘌呤-2,6,8-三硫酮
• 英文名称: trithiouric acid
• 英文别名: Trithioharnsaeure；2,6,8-trithiouric acid；7,9-dihydro-3H-purine-2,6,8-trithione
• CAS: 15986-33-1
• 化学式: C₅H₄N₄S₃
• mdl: MFCD03939067
• 分子量: 216.312
• InChiKey: ITERHBFDXIEMFW-UHFFFAOYSA-N

物化性质

• 沸点：
  314.0±52.0 °C(Predicted)
• 密度：
  1.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7,9-二氢-3H-嘌呤-2,6,8-三硫酮 、 碘甲烷 在 sodium hydroxide 作用下， 生成 2,6,8-tris-methylsulfanyl-7(9)H-purine
  参考文献：
  名称：

  Potential Purine Antagonists. XX. The Preparation and Reactions of Some Methylthiopurines¹

  摘要：

  DOI：

  10.1021/ja01531a037
• 作为产物：
  描述：

  8-氯-1H-嘌呤-2,6(3h,7h)-二酮 在 水 、 potassium hydrosulfide 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 生成 7,9-二氢-3H-嘌呤-2,6,8-三硫酮
  参考文献：
  名称：

  Garkuscha, Zhurnal Obshchei Khimii, 1957, vol. 27, p. 1712,1715;engl.Ausg.S.1783,1785

  摘要：

  DOI：

文献信息

• Fischer,E., Chemische Berichte, 1898, vol. 31, p. 438
  作者：Fischer,E.

  DOI：——

  日期：——
• DE100875
  申请人：——

  公开号：——

  公开（公告）日：——
• The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein–protein interaction
  作者：Nelly A. Fosu-Mensah、Wen Jiang、Andrea Brancale、Jun Cai、Andrew D. Westwell

  DOI：10.1007/s00044-018-2275-9

  日期：2019.2

  Oestrogen receptor-negative breast cancer, particularly subtypes such as triple-negative breast cancer (TNBC, around 10-15% of cases), are characterised by poor long-term survival, poor response to therapy and early progression to metastasis. Purine-based compounds represent a privileged scaffold in anticancer drug design, with several clinically approved and experimental agents in clinical development comprising a purine core structure. In this study, a series of new purine-based compounds were synthesised; seven of the new analogues were found to significantly reduce the in vitro viability of TNBC cell lines (MDA-MB-231 and MDA-MB-436) with IC50 values of 50M. In previous work, we have proposed a new concept for targeting angiogenesis driving TNBC progression, by disrupting the protein-protein interaction between the molecular chaperone B-crystallin (CRYAB) and VEGF. Since previous clinical studies applying anti-VEGF therapy to TNBC patients have met with limited success, we were interested to test our most promising purine analogues against CRYAB/VEGF, using a custom-designed cell-based CRYAB/VEGF(165) interaction assay platform. Analogues 4e and 4f significantly reduced the interaction between CRYAB/VEGF(165), and compound 4e (100M) was also found to decrease the levels of soluble VEGF expressed by MDA-MB-231 cells by 40%. In conclusion, these promising early activity profiles warrant further investigation to validate this concept.
• Garkuscha, Zhurnal Obshchei Khimii, 1957, vol. 27, p. 1712,1715;engl.Ausg.S.1783,1785
  作者：Garkuscha

  DOI：——

  日期：——
• Potential Purine Antagonists. XX. The Preparation and Reactions of Some Methylthiopurines¹
  作者：C. Wayne Noell、Roland K. Robins

  DOI：10.1021/ja01531a037

  日期：1959.11